Xortx Therapeutics INC. 6-K Filing
Ticker: XRTX · Form: 6-K · Filed: Apr 1, 2026 · CIK: 0001729214
Sentiment: neutral
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2026-04-01 13:00:04
Filing Documents
- f6k_040126.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 6KB
- 0001171843-26-002162.txt ( ) — 11KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: April 1, 2026 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated April 1, 2026